Home › Funds › Catalio Capital Management, LP › IMCR
Catalio Capital Management, LP position in IMCR
IMMUNOCORE HLDGS PLC · Health Care
Catalio Capital Management, LP reported holding 148,045 shares of IMCR (IMMUNOCORE HLDGS PLC) in its Q2 2026 13F filing — a position valued at US$4.7M, representing 0.88% of its reported portfolio and ranking #31 among its reported holdings. Catalio Capital Management, LP has disclosed IMCR holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Catalio Capital Management, LP's IMCR position evolved
Catalio Capital Management, LP first disclosed a stake in IMCR in Q1 2026 at 84,352 shares (US$2.5M). The position peaked in Q2 2026 at 148,045 shares, worth US$4.7M. Across 2 filings, Catalio Capital Management, LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 148,045 shares valued at US$4.7M — an increase of 63,693 shares quarter over quarter.. Notable position changes include a 76% increase in Q2 2026 (shares fell 5% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 84.35K | $2.54M | New |
| Q2 2026 | 148.04K | $4.70M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About IMCR and 13F data
IMCR (IMMUNOCORE HLDGS PLC) is a Health Care company. 32 other funds we track also report a position in IMCR — the largest reported positions include RTW INVESTMENTS, LP (US$154.6M), Bellevue Group AG (US$88.5M), TANG CAPITAL MANAGEMENT LLC (US$84.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding IMCR
- RTW INVESTMENTS, LP 4.87M sh · $154.62M · Q2 2026
- Bellevue Group AG 2.79M sh · $88.53M · Q2 2026
- TANG CAPITAL MANAGEMENT LLC 2.65M sh · $84.12M · Q2 2026
- Vestal Point Capital, LP 1.80M sh · $57.15M · Q2 2026
- ARMISTICE CAPITAL, LLC 1.43M sh · $45.34M · Q2 2026
- Caligan Partners LP 1.38M sh · $43.86M · Q2 2026
- Kynam Capital Management, LP 1.38M sh · $43.66M · Q2 2026
- BVF INC/IL 1.29M sh · $41.10M · Q2 2026
- Trails Edge Capital Partners, LP 1.06M sh · $33.76M · Q2 2026
- Logos Global Management LP 600.00K sh · $19.05M · Q2 2026
- Jones Hill Capital LP 512.86K sh · $16.28M · Q2 2026
- Frazier Life Sciences Management, L.P. 484.78K sh · $15.39M · Q2 2026
More on Catalio Capital Management, LP
FAQ
How long has Catalio Capital Management, LP held IMCR?
Catalio Capital Management, LP has disclosed IMCR holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is Catalio Capital Management, LP's current position in IMCR?
As of Q2 2026, Catalio Capital Management, LP holds 148.04K shares of IMCR (IMMUNOCORE HLDGS PLC), valued at $4.70M, representing 0.88% of its reported portfolio and ranking #31.
Has Catalio Capital Management, LP been buying or selling IMCR?
In the latest 13F filing (Q2 2026), Catalio Capital Management, LP increased its position in IMCR. The position peaked in Q2 2026 at 148.04K shares.
Which other funds hold IMCR?
Other major institutional holders of IMCR include RTW INVESTMENTS, LP, Bellevue Group AG, TANG CAPITAL MANAGEMENT LLC, among 32 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.